LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced today that it has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration, conducted through LataMed AI's Venezuelan operating subsidiary LATAMEDAI VE, aims to design, develop, test, and evaluate customized technology to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The parties will begin by identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process. They also intend to establish appropriate confidentiality, information-security, data-management, and access-control procedures.
The initiative is significant because it marks a strategic expansion for LataMed AI beyond its patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The collaboration aligns with LataMed AI's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other participants in the healthcare ecosystem. If successfully developed and implemented, management believes the resulting technology may provide a framework that could potentially be adapted for other pharmaceutical, laboratory, and healthcare organizations in Venezuela and elsewhere in Latin America. Any future expansion would remain subject to separate agreements, successful development and testing, operational readiness, applicable regulatory requirements, and the needs of participating organizations.
The parties will also evaluate the ownership, licensing, permitted use, and protection of any software, technology, data, or other intellectual property developed through the collaboration. The specific intellectual-property and commercialization terms will be governed by the agreement and any additional documentation entered into by the parties. The agreement establishes the framework under which LataMed AI and DROGUERIAS LALA C.A. intend to develop and evaluate the proposed technology. It does not guarantee a specific implementation schedule, commercial deployment, reduction in operating costs or development timelines, scientific or regulatory outcomes, revenue, profitability, or expansion to additional organizations.
Importantly, any pharmaceutical, scientific, laboratory, or quality-control determinations will remain the responsibility of appropriately qualified professionals and applicable regulatory authorities. The proposed technology would not replace the independent professional judgment of scientists, pharmacists, laboratory personnel, healthcare providers, or other authorized professionals. The Company will provide additional information regarding development, testing, and potential implementation as appropriate. For additional information, please visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
